Clinical Trials Logo

Ventricular Premature Complexes clinical trials

View clinical trials related to Ventricular Premature Complexes.

Filter by:

NCT ID: NCT06327425 Not yet recruiting - Atrial Fibrillation Clinical Trials

MCG for Localization of Tachyarrhythmia's Origin

Start date: March 14, 2024
Phase: N/A
Study type: Interventional

This is an exploratory research aiming to accurately identify the site of origin of tachyarrhythmia using Magnetocardiography (MCG), which will have guiding significance for early diagnosis, the formulation of treatment plans and preoperative positioning for radiofrequency ablation.

NCT ID: NCT06203262 Not yet recruiting - Clinical trials for Ventricular Tachycardia

Ventricular Catheter Ablation Study (VCAS)

VCAS
Start date: March 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective safety and feasibility study to evaluate the safety of the FieldForceâ„¢ Ablation system in patients with ventricular arrhythmia divided into two groups: VT (VCAS-I) and frequent premature ventricular complex (VCAS-II).

NCT ID: NCT06146556 Not yet recruiting - Clinical trials for Premature Ventricular Contractions

Concealed Myocardial Abnormalities by Cardiac Magnetic Resonance Imaging in Idiopathic VT

Start date: January 1, 2024
Phase:
Study type: Observational

Idiopathic Ventricular arrhythmia (VAs) refers to VAs that occur in the absence of clinically apparent structural heart disease. The outflow tracts (OTs) are the most common origin of idiopathic VAs and PVCs, accounting for approximately 10% of all patients referred for evaluation of VAs with the RVOT being the origin of about 70-80% of these arrhythmias. Studies have shown that increased PVC burden was associated with reduced LV function, a higher incidence of heart failure, and a higher risk of death. The diagnosis, prognostication and treatment of patients with VAs are challenging. A routine diagnostic workup that includes transthoracic echocardiography and an assessment for the presence of coronary artery disease (CAD) as recommended by current clinical guidelines cannot recognize focal structural abnormalities or underlying structural heart disease (SHD) in a substantial proportion of patients. Cardiac magnetic resonance (CMR) provides an excellent assessment of cardiac morphology and function and enables a detailed myocardial tissue characterization with a high degree of precision. CMR is widely regarded as the gold standard for identifying structural arrhythmogenic substrates in patients with VAs and normal echocardiography.

NCT ID: NCT06110364 Not yet recruiting - Clinical trials for Premature Ventricular Contraction

Vagal Nerve Stimulation as an Alternative Therapy for Premature Ventricular Contractions

Start date: October 2023
Phase: Phase 3
Study type: Interventional

Prospective randomized control pilot study

NCT ID: NCT06060548 Recruiting - Myocarditis Clinical Trials

Role of Novel ILR in the Management of PVCs

Start date: April 20, 2022
Phase:
Study type: Observational

This prospective, observational study is a single center clinical registry of patients referred for management of symptomatic or asymptomatic Premature Ventricular Contractions (PVCs). Subjects will be followed through 12 months. The study will enroll approximately 50 patients.

NCT ID: NCT06021613 Recruiting - Clinical trials for Premature Ventricular Contractions

The MARY-JANE Cannabis and Heart Rhythm Trial

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

Despite recreational cannabis now being legal in 23 states, where more than 100 million Americans reside, studies on the actual health effects are limited. This study is a randomized trial, where each participant will be instructed to consume or avoid cannabis on randomly assigned days during a 14-day monitoring period. The goal of this study is to answer the question: "Does cannabis use increase the frequency of 'early' and abnormal heart beats?" During the 14-day period, participants will wear an external heart monitor, a glucose monitor, and a fitness tracker to track heart rhythm, glucose levels, step counts, and sleep health. Participants will use a mobile app or a text messaging service for daily instructions/reminders on cannabis use, and short surveys. The investigators ask that participants smoke or vape cannabis at least once on days they are instructed to consume cannabis. Compelling evidence of heart and other health effects would be important to the clinical care of our patients.

NCT ID: NCT05970120 Recruiting - Clinical trials for Ventricular Tachycardia

A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter

Start date: September 5, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the performance and safety of using the investigational catheter.

NCT ID: NCT05903313 Enrolling by invitation - Clinical trials for Myocardial Infarction

A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software

Start date: October 6, 2023
Phase:
Study type: Observational

"Chang Gung ECG Abnormality Detection Software" is a is an artificial intelligence medical signal analysis software that detect whether patients have abnormal ECG signals of 14 diseases by static 12-lead ECG. The 14 diseases were - Long QT syndrome - Sinus bradycardia - Sinus Tachycardia - Premature atrial complexes - Premature ventricular complexes - Atrial Flutter, Right bundle branch block - Left bundle branch block - Left Ventricular hypertrophy - Anterior wall Myocardial Infarction - Septal wall Myocardial Infarction - Lateral wall Myocardial Infarction - Inferior wall Myocardial Infarction - Posterior wall Myocardial Infarction The main purpose of this study is to verify whether "Chang Gung ECG Abnormality Detection Software" can correctly identify abnormal ECG signals among patients of 14 diseases. The interpretation standard is the consensus of 3 cardiologists. The results of the software analysis will be used to evaluate the performance of the primary and secondary evaluation indicators.

NCT ID: NCT05866731 Recruiting - Clinical trials for Premature Ventricular Contraction

The Heart Rhythm Twins Study

Start date: March 22, 2022
Phase:
Study type: Observational

Premature atrial contractions (PACs) and premature ventricular contractions (PVCs) are observed in the majority of individuals monitored for more than a few hours. Although the clinical course of PACs and PVCs is usually benign, it has been described that high PAC or PVC frequency causes various comorbidities and worsens outcomes in different patient groups. For example, PACs can initiate episodes of atrial fibrillation, and PAC count is highly specific in predicting diagnosis of incident atrial fibrillation. Increasing PVC frequencies are an important predictor of incident heart failure. While conventional wisdom dictates that common environmental exposures determine PAC and PVC frequencies, this has not born out in rigorous studies. Whether PAC and PVC frequencies may have genetic underpinnings remains unknown. Comparisons between identical twins and fraternal twins can provide estimates of heritability. Fraternal twins are an ideal control because, like identical twins, they share a womb, have the same birthday, and their environment while growing up are as similar as between identical twins. However, while identical twins share approximately 100% of the same inherited DNA, fraternal twins share, on average, about 50%. By monitoring identical and fraternal twins with portable electrocardiograms (ECGs), we will be able to count the PACs and PVCs over a consecutive timespan to describe the familial aggregation of these complexes. This, to our knowledge, would be the first study to compare PAC and PVC frequencies in identical and same-sex fraternal twins, providing the first assessment of how genetical inheritance may influence cardiac ectopy burdens.

NCT ID: NCT05784051 Not yet recruiting - Clinical trials for Ventricular Dysfunction, Left

Prophylactic Frequent Premature Ventricular complexeS sUPPression on Left ventriculaR Function impairmEnt in aSymptomatic patientS

SUPPRESS
Start date: October 1, 2023
Phase: Phase 4
Study type: Interventional

The main objective of the study is to demonstrate that prophylactic treatment of patients with asymptomatic frequent (>10%) PVCs is superior to simple follow-up strategy with no therapy to prevent subsequent LV dysfunction at 24 months. The prophylactic treatment is based on drugs ± ablation (ablation can be performed if the PVC burden remain >10% after 2 lines of AAD treatment since the initiation of the study). The primary endpoint will be the development of LV dysfunction (PVC-iCMP) defined as a 15% relative LVEF decrease (and/or a LVEF <50%) within 2 years following randomization, on cardiac magnetic resonance imaging (cMRI) (or transthoracic echocardiography (TTE) when not possible).